

## ADURS2021 Speakers Titles/Objectives

### Thursday, February 25, 2021

**Maria M. Lowe, PharmD, BCPS**, Director of Pharmaceutical Intelligence, Institute for Clinical and Economic Review

**Title:** Pipeline Preview 2021

**ACPE UAN:** 0128-9999-21-005-L01-P

**CPE:** 1.5 contact hours / Knowledge-based CPE activity

**Objectives:**

1. Describe recent trends in the FDA approval process.
2. Describe agents in the late-stage pipeline across key therapeutic areas.
3. Identify generic equivalents for commonly used brand-name products that will be introduced to the market over the next two years.

**Donnie Sullivan, RPh, PhD**, Clinical Professor of Pharmacy, OH State University College of Pharmacy

**Title:** The Changing Face of Prescription Diversion

**ACPE UAN:** 0128-9999-21-006-L04-P

**CPE:** 1.0 contact hour / Knowledge-based CPE activity

**Objectives:**

1. Describe common prescribing patterns physicians use to hide prescription drug abuse and diversion in patients.
2. Describe recent combinations, trends, and “cocktails” of prescription drug diversion.
3. Describe identification and assessment techniques in finding drug diversion/drug abuse with controlled substance prescriptions.
4. Describe common techniques pharmacists can use to combat drug diversion.

**Clemice Hurst, RPh**, Clinical Pharmacist, Alabama Medicaid Agency/Kepro

**Title:** State Roundtable - State Medicaid Programs (Part 1)

**ACPE UAN:** 0128-9999-21-007-L04-P

**CPE:** 1.5 contact hours / Knowledge-based CPE activity

**Objectives:**

1. Define retroDUR methodologies and processes utilized by State Medicaid Programs and explain how retroDUR impacts State Medicaid patient health and fiscal outcomes.
2. Identify factors that contribute to the successes and challenges of State Medicaid programs medication management initiatives.
3. Describe DUR initiatives based upon the proposal phase, implementation phase, program delivery, and outcome evaluation phase.

### Friday, February 26, 2021

**Thomas Frank, PharmD, BCPS**, Frank Medical Consulting

**Title:** Things We Do For No Reason

**ACPE UAN:** 0128-9999-21-008-L01-P

**CPE:** 1.0 contact hour / Knowledge-based CPE activity

**Objectives:**

1. Identify reasons we may accept unproven practices as dogma.
2. Describe the benefits of challenging a questionable penicillin allergy history.
3. Explain the potential benefits of evaluating extended drug expiration dates.

**Jordan Brazeal, PharmD**, Pharmacy Consultant

**Title:** New Drug Review 2020

**ACPE UAN:** 0128-9999-21-017-L01-P

**CPE:** 1.5 contact hours / Knowledge-based CPE activity

**Objectives:**

1. List indications, pharmacology, adverse effects, and dosing of select new products.
2. Examine the clinical efficacy and applicability of these products.
3. Identify possible prior authorization pathways for these products.
4. Describe the economic implications of these products on state Medicaid programs.

**Clemice Hurst, RPh**, Clinical Pharmacist, Alabama Medicaid Agency/Kepro

**Title:** State Roundtable - State Medicaid Programs (Part 2)

**ACPE UAN:** 0128-9999-21-009-L04-P

**CPE:** 1.5 contact hours / Knowledge-based CPE activity

**Objectives:**

1. Define retroDUR methodologies and processes utilized by State Medicaid Programs and explain how retroDUR impacts State Medicaid patient health and fiscal outcomes.
2. Identify factors that contribute to the successes and challenges of State Medicaid programs medication management initiatives.
3. Describe DUR initiatives based upon the proposal phase, implementation phase, program delivery, and outcome evaluation phase.

**On-Demand Presentations. CE credit available through Saturday, March 13, 2021 ONLY.**

**Joshua Moore, PharmD**, Director of Pharmacy, MO HealthNet, State of Missouri

**Title:** Oral Oncology Management – Baby Steps

**ACPE UAN:** 0128-9999-21-010-H04-P

**CPE:** 0.5 contact hour / Knowledge-based CPE activity

**Objectives:**

1. Identify one method to potentially reduce wasted medication by limiting initial fills of oral oncology medications.
2. Compute cost avoidance for implementing initial fill limitations.
3. Cite evidence for implementing a similar control in your state Medicaid program.

**Emily Baker, PharmD, BCPS, MBA, MHA**, President, NorthStar HealthCare Consulting

**Title:** The SUPPORT Act, Physician Administered Drugs, and the Potential for Fraud, Waste, and Abuse.

**ACPE UAN:** 0128-9999-21-011-H03-P

**CPE:** 0.5 contact hour / Knowledge-based CPE activity

**Objectives:**

1. Identify the medication coverage requirements for opioid use disorders (OUD) as required by the SUPPORT Act.
2. List medications for OUD that may be administered by a physician.
3. Discuss the potential for Fraud, Waste, and Abuse including duplicate claims.
4. Identify the role of program integrity efforts including audits.

**Amanda Ka, PharmD**, Account Consultant Pharmacist, Clinical Account Manager, OptumRx, Indiana Medicaid

**Title:** Pharmacy Audit Pharmacists – Indiana Experience

**ACPE UAN:** 0128-9999-21-012-H04-P

**CPE:** 0.5 contact hour / Knowledge-based CPE activity

**Objectives:**

1. Identify potential benefits to utilizing a pharmacist with pharmacy claims auditing.
2. Describe audit findings and clinical programs implemented to address these findings in Indiana Medicaid.
3. List educational tactics that can be used to increase pharmacy compliance.

**Cori Cooper, PharmD**, Medicaid Pharmacy Program Manager, Wyoming Department of Health

**Title:** Pearl: Pharmacy Audit Pharmacist: The Benefits of Having a Pharmacist Conducting Program Integrity Reviews

**ACPE UAN:** 0128-9999-21-013-H04-P

**CPE:** 0.5 contact hour / Knowledge-based CPE activity

**Objectives:**

1. Describe the Wyoming Medicaid Program Integrity Pharmacist's role and processes for reviewing pharmacy claims.
2. List three projects undertaken by the Wyoming Program Integrity Pharmacist that have identified issues with claims and improved the quality of pharmacy claims submissions.
3. Review the financial savings achieved through the Pharmacy Program Integrity work.

**Carol Ott, PharmD, BCPP**, Clinical Professor of Pharmacy Practice, Purdue Univ. College of Pharmacy; Clinical Pharmacy Specialist, Psychiatry & Gender Health, Eskenazi Health, Indianapolis, IN

**Title:** Gender Affirming Treatment: Review of Medications, Treatment Guidelines, and Barriers to Treatment

**ACPE UAN:** 0128-9999-21-014-H01-P

**CPE: 1.0 contact hour** / Knowledge-based CPE activity

**Objectives:**

1. Describe drug therapy that is used in gender affirming treatment, including hormone therapy, GnRH analogs, spironolactone, bicalutamide, and finasteride.
2. List the most commonly used gender affirmation treatment guidelines, including the World Professional Association for Transgender Health (WPATH), Endocrine Society, and UCSF Guidelines for Gender-Affirming Care.
3. Identify the diagnostic criteria for gender dysphoria based upon the Diagnostic and Statistical Manual, 5<sup>th</sup> edition (DSM-5)
4. Outline medical and non-medical barriers to receiving gender-affirming care, including issues of stigma and discrimination.

**Steve Liles, PharmD**, Senior Director, Industry Relations, Pharmacy Benefit Solutions, Change Healthcare

**Title:** FDA Expedited Review – Pathways to Value or Shortcuts to Profits?

**ACPE UAN:** 0128-9999-21-015-H04-P

**CPE: 1.0 contact hour** / Knowledge-based CPE activity

**Objectives:**

1. Describe the primary purpose of the FDA's expedited approval pathways.
2. Explain the differences between a standard review and a priority review.
3. Identify the expedited approval type that requires the manufacturer to conduct phase 4 confirmatory trials.
4. Name a drug that has recently received EUA.

**Cynthia Denmark, RPh**, Deputy Director, Division of Pharmacy, Center for Medicaid & CHIP Services, Centers for Medicare & Medicaid Services

**Title:** CMS Medicaid Division of Pharmacy Update 2021

**ACPE UAN:** 0128-9999-21-018-H04-P

**CPE: 1.0 contact hour** / Knowledge-based CPE activity

**Objectives:**

1. List the sections of the SUPPORT Act that apply to drugs.
2. Examine trends and innovations used for drug utilization review programs across the country.
3. Identify disease states that can lead to beneficial retrospective utilization projects.



The **2021 ADURS Symposium** is designed for pharmacists specializing in medication utilization within State Medicaid programs and is sponsored by the American Drug Utilization Review Society (ADURS) and the Nebraska Pharmacy Association (NPA). NPA is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Credit for courses must be earned by the participant. Participants will earn **13.0 contact hours** of continuing pharmacy education (CPE) credits for attendance of the entire symposium.

In order to earn CPE credits, the participant must complete an on-line educational evaluation form for each CPE session they attend within 15 days from the end of the symposium. The evaluation will collect birthdates (MMDD) and NABP e-Profile ID numbers (to receive CPE credits, the attendee must have an NABP e-Profile ID number). For more information about NABP e-Profile IDs, please see <https://nabp.pharmacy/programs/cpe-monitor/>. ACPE CPE numbers and speaker objectives can be found in the program schedule. **CPE credits will be sent to your NABP e-Profile within 45 days of the program date.** For questions about CPE credits, please email Loralyn Joyce at [ljoyce.adurs@gmail.com](mailto:ljoyce.adurs@gmail.com).